Sugi Predict

Sugi Predict / Targets / SLC33A1

SLC33A1

Acetyl-coenzyme A transporter 1 · O00400 · SLC33A1 on Sugi Atlas →

3,739 patent compounds predicted against SLC33A1, 2,364 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1369650 SCHEMBL1369650 1.00 20/20
SCHEMBL1369651 SCHEMBL1369651 1.00 20/20
SCHEMBL1370023 SCHEMBL1370023 1.00 20/20
SCHEMBL1370026 SCHEMBL1370026 1.00 20/20
SCHEMBL1370052 SCHEMBL1370052 1.00 20/20
SCHEMBL1370217 SCHEMBL1370217 1.00 20/20
SCHEMBL1370218 SCHEMBL1370218 1.00 20/20
SCHEMBL1370234 SCHEMBL1370234 1.00 20/20
SCHEMBL1370236 SCHEMBL1370236 1.00 20/20
SCHEMBL1370237 SCHEMBL1370237 1.00 20/20
SCHEMBL1370238 SCHEMBL1370238 1.00 20/20
SCHEMBL1370245 SCHEMBL1370245 1.00 20/20
SCHEMBL1370246 SCHEMBL1370246 1.00 20/20
SCHEMBL1370248 SCHEMBL1370248 1.00 20/20
SCHEMBL1370249 SCHEMBL1370249 1.00 20/20
SCHEMBL1370290 SCHEMBL1370290 1.00 20/20
SCHEMBL1370304 SCHEMBL1370304 1.00 20/20
SCHEMBL1370339 SCHEMBL1370339 1.00 20/20
SCHEMBL1370342 SCHEMBL1370342 1.00 20/20
SCHEMBL1370468 SCHEMBL1370468 1.00 20/20

Clinical trials — most relevant to SLC33A1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
L-arginine Treatment in Mild Hypertension PHASE4UNKNOWN
Pharmacological Regulation of Fat Transport in Metabolic Syndrome PHASE4COMPLETED
Chronic Versus Acute Dosing of Sodium Citrate for Swimming 200m PHASE3COMPLETED
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients PHASE2COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease PHASE2COMPLETED
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC PHASE1/PHASE2UNKNOWN
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis PHASE2UNKNOWN
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy PHASE2ACTIVE_NOT_RECRUITING
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) PHASE2COMPLETED
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies PHASE1COMPLETED
Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension PHASE1COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters EARLY_PHASE1COMPLETED
Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol EARLY_PHASE1COMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED
Oxalate and Citrate in Humans - Response to Citrate nanRECRUITING
Expression of SLC25A48 in Chronic Obstructive Pulmonary Disease nanNOT_YET_RECRUITING
MOLECULAR REGULATION OF MUSCLE GLUCOSE METABOLISM (AIMS 2A, 2B, 3) nanUNKNOWN
Transporter Mediated Uptake of Montelukast nanCOMPLETED
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts nanCOMPLETED
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs nanCOMPLETED
11C-Acetate PET/CT Non-FDG-Avid Tumors nanUNKNOWN
The Role of Arachidonic Acid Metabolites, From Patients With Metabolic Syndrome nanUNKNOWN
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides nanCOMPLETED
Oxalate and Citrate nanRECRUITING
Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study nanRECRUITING
Epidemiology of Atherosclerosis nanCOMPLETED
The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux nanCOMPLETED
Triheptanoin (UX007) to Treat Citrate Transporter Deficiency nanNO_LONGER_AVAILABLE
Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a SLC33A1 binder may also engage these)

ProteinNameSimilarity
Q6AYY8 — 1.000 Q6AYY8 →
Q99J27 — 1.000 Q99J27 →
Q8RWQ5 — 0.988 Q8RWQ5 →
Q9UMX9 — 0.986 Q9UMX9 →
Q4LE88 — 0.986 Q4LE88 →
A2X6E6 — 0.985 A2X6E6 →
Q6GMG6 — 0.985 Q6GMG6 →
Q55721 — 0.984 Q55721 →
Q6BZW3 — 0.984 Q6BZW3 →
Q9C8X2 — 0.983 Q9C8X2 →
Q1KKV8 — 0.983 Q1KKV8 →
Q9USW4 — 0.982 Q9USW4 →
Q69JW3 — 0.982 Q69JW3 →
SLC15A2 Solute carrier family 15 member 2 0.981 landscape →
SLC6A19 Sodium-dependent neutral amino acid transporter B(0)AT1 0.981 landscape →
P46029 — 0.981 P46029 →
P38318 — 0.981 P38318 →
A6SSM3 — 0.981 A6SSM3 →
Q5AVT9 — 0.980 Q5AVT9 →
B0S5Y3 — 0.980 B0S5Y3 →
Q0TWF4 — 0.980 Q0TWF4 →
O23596 — 0.980 O23596 →
Q28E13 — 0.979 Q28E13 →
A2VE54 — 0.979 A2VE54 →
Q4WZY1 — 0.979 Q4WZY1 →
Q9Y115 — 0.979 Q9Y115 →
Q9ES07 — 0.979 Q9ES07 →
A1A4N1 — 0.979 A1A4N1 →
Q63424 — 0.979 Q63424 →
Q9XIQ7 — 0.979 Q9XIQ7 →